Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens: a Multicenter, International, Prospective, Non-interventional Study in Germany and Austria (TRACE)

NCT05253911 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT05253911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens: a Multicenter, International, Prospective, Non-interventional Study in Germany and Austria (TRACE)
Lead sponsor
iOMEDICO AG
Phase
Observational
Overall status
Completed
Start date
May 21, 2022
Completion date
June 30, 2025
Enrollment
49 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer